Successful crizotinib monotherapy in EGFR-mutant lung adenocarcinoma with acquired MET amplification after erlotinib therapy

MET is a driver oncogene in non-small-cell lung cancer (NSCLC), and its amplification is associated with acquired resistance to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors. A 56-year-old Japanese male with lung adenocarcinoma harboring an EGFR exon 21 L858R mutation received e...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Respir Med Case Rep
Egile Nagusiak: Yoshimura, Katsuhiro, Inui, Naoki, Karayama, Masato, Inoue, Yusuke, Enomoto, Noriyuki, Fujisawa, Tomoyuki, Nakamura, Yutaro, Takeuchi, Kengo, Sugimura, Haruhiko, Suda, Takafumi
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Elsevier 2017
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5322209/
https://ncbi.nlm.nih.gov/pubmed/28271038
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.rmcr.2017.02.009
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak